Citurgia Biochemicals Limited has closed its trading window for dealing in company securities effective October 1, 2026. The closure remains in effect until 48 hours after the declaration of the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026.

This action is taken in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended by the 2018 amendment regulations. It also adheres to the company's internal Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons.

Board meeting schedule

The company stated that the specific date of the board meeting for considering and approving the financial results will be intimated in due course. Investors should monitor subsequent filings for this confirmation.

Compliance details

The trading window closure applies to all designated persons within the organization. This standard procedure prevents insider trading during the sensitive period leading up to the release of financial performance data.

Krebs Biochemicals & Industries Limited concluded its 34th Annual General Meeting on September 29, 2026, with all five ordinary resolutions passed by requisite majority. The meeting, held via Video Conferencing, covered FY26 financial adoption, director reappointments, and related party transaction approvals.

Voting results and scrutiny

The scrutinizer’s report confirmed that 156.78 lakh votes were polled across the resolutions. For the adoption of audited financial statements (Resolution 1), promoters and promoter group cast 1.57 crore votes in favour, representing 99.87% of their holding. Public non-institutional shareholders recorded a minor dissent of 213 votes (1.51% of votes polled by this category), but the resolution passed comfortably with 99.99% total support.

Director reappointments for Dr. R T Ravi and Mr. Manish Kumar Jain also secured overwhelming backing. In both cases, promoter group votes were unanimous in favour. Public non-institutional dissent remained marginal, ranging between 1.50% and 3.41% of votes polled by that specific category, ensuring passage of both resolutions.

Related party transactions and auditor remuneration

Approval for related party transactions with Ipcia Laboratories Limited (Resolution 4) was notable for the exclusion of promoter votes, as the promoter group was interested in the agenda. Consequently, only public shareholders voted on this item. The resolution received 6,097 votes in favour against 216 votes against, resulting in a 96.58% approval rate among participating public shareholders.

The ratification of cost auditor remuneration (Resolution 5) saw similar patterns to the financials adoption, with promoters voting unanimously in favour and public non-institutional dissent at 1.53% of their polled votes.

Meeting attendance and process

Electronic voting facilities were provided from September 25 to September 28, 2026. Ms. Kritika Sharma, Practicing Company Secretary, served as the Scrutinizer. The results were declared after the receipt of her report.

Attendance data revealed that while no shareholders attended physically or through proxy, 43 members participated via video conferencing: 3 from the promoter group and 40 from the public. The meeting commenced at 11:30 am and concluded at 12:15 pm.